non-SMC condensin I complex subunit D2 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored NCAPD2P1 profile across patient tissues and cancer cell-line models. NCAPD2P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NCAPD2P1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NCAPD2P1 RNA expression shows 10,012 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where NCAPD2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCAPD2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCAPD2P1 survival associations across molecular data types. NCAPD2P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCAPD2P1 RNA expression–survival associations across cancer types. High NCAPD2P1 expression shows unfavorable associations in KIRC, MESO, DLBC, LIHC, LGG and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NCAPD2P1 RNA expression.
This table summarizes NCAPD2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NCAPD2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCAPD2P1 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in COAD, LIHC and HNSC. The KIRC box plot shows higher NCAPD2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.363, t-test p < 0.001).
This table shows molecular features associated with NCAPD2P1 in patient tissues and cancer cell lines. In patient samples, NCAPD2P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
